|
0
|
|
Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.
(linkinghub.elsevier.com)
|
Hisamoto K
…
Sawata M
Lancet Infectious Diseases
2026-08-03
|
#vaccination
#clinical trial
#hpv
#immunogenicity
#efficacy
|
|
0
|
|
Two-year durability of MVA-BN vaccine-induced antibodies and the risk of Mpox breakthrough infections among high-risk populations: a prospective, longitudinal study.
(linkinghub.elsevier.com)
|
Liu WD
…
Hung CC
Clinical Microbiology and Infection
2026-08-03
|
#vaccination
#immunogenicity
#mpox
#serology
#durability
|
|
0
|
|
Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses.
(linkinghub.elsevier.com)
|
Chen H
…
Lu S
Cell Reports Medicine
2026-08-03
|
#vaccination
#immunology
#antibody
#transcriptomics
#immunogenicity
|
|
0
|
|
A bivalent inactivated influenza vaccine incorporating epitope-optimized surface proteins confers cross-protective immunity against H9N2 influenza virus.
(tandfonline.com)
|
Hao M
…
Chen J
Emerging Microbes & Infections
2026-08-03
|
#vaccination
#influenza
#epitope
#immunogenicity
#zoonosis
|
|
0
|
|
A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes.
(academic.oup.com)
|
Pardo-Seco J
…
Martinon-Torres F
Clinical Infectious Diseases
2026-08-03
|
#vaccination
#influenza
#elderly
#immunogenicity
|
|
0
|
|
Optimizing infectious disease mitigation under dynamic conditions.
(pnas.org)
|
Muller L
…
Priesemann V
PNAS
2026-08-03
|
#modeling
#epidemiology
#optimization
#pandemic
#vaccination
|